Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome [clinicaltrials:NCT00149240]

Bio2RDF uri

Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome [clinicaltrials:NCT00149240]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00149240

Bio2RDF identifier

NCT00149240

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00149240

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00149240

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:35c21a60e73f3706d3b98dc6a1440f1a

brief summary [clinicaltrials_vocabulary:brief-summary]

The main purpose of thi ...... ary myofascial pain syndrome.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Botulinum Toxin Type A (Dyspor ...... imary Myofascial Pain Syndrome

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

The following parameters are measured at Inclusion, Week 2, Week 4, Week 8 and Week 12 of the study: [clinicaltrials_resource:351b27c708f6614e63e2d6aae018713c]

The following parameters are measured at Inclusion, Week 2, Week 4, Week 8 and Week 12 of the study: [clinicaltrials_resource:4ad16bb5460ba7982ac19a8bb4ddcc84]

The following parameters are measured at Inclusion, Week 2, Week 4, Week 8 and Week 12 of the study: [clinicaltrials_resource:920c4cb23a524592a83e0fbe00f224dd]

The following parameters are measured at Inclusion, Week 2, Week 4, Week 8 and Week 12 of the study: [clinicaltrials_resource:9d5320d9964ebb8b5935bb0da9eef845]

The following parameters are measured at Inclusion, Week 2, Week 4, Week 8 and Week 12 of the study: [clinicaltrials_resource:a4faf0163850db3546a062b76e0a2f24]

completion date [clinicaltrials_vocabulary:completion-date]

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00149240 [clinicaltrials_resource:a5a8bb27cdea49df093fc9422873aa92]

enrollment [clinicaltrials_vocabulary:enrollment]

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Botulinum toxin type A (Dysport) [clinicaltrials_resource:224ba049cbd4f221b24da46af5116cad]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Botulinum Toxins [clinicaltrials_resource:72c2ec52af3cc2352301bc69055f6f26]

Botulinum Toxins, Type A [clinicaltrials_resource:edca97403b813ba86b3d465f46f84466]

keyword [clinicaltrials_vocabulary:keyword]

DYSPORT

http://www.w3.org/2001/XMLSchema#string

botulinum toxin A

http://www.w3.org/2001/XMLSchema#string

myofascial pain syndrome

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2007-04-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Ipsen [clinicaltrials_resource:72e24e8f01584e350155390bbce36547]

location [clinicaltrials_vocabulary:location]

University Hospital "Vall d 'Hebrón". Barcelona [clinicaltrials_resource:fc79e1394e3d1ffabc05260cd23a0189]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00149240

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

A Phase II, Multicentre, Rando ...... rvical and Dorsal Localisation

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

A-92-52120-089

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Mónica de Abadal, MD [clinicaltrials_resource:4d7813e19bf02dab63ec01b6ddd6b9e8]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Spain: Ministry of Health [clinicaltrials_resource:f72bf712730417d99f88947ed22af3a2]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

source [clinicaltrials_vocabulary:source]

Ipsen [clinicaltrials_resource:72e24e8f01584e350155390bbce36547]

start date [clinicaltrials_vocabulary:start-date]

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00149240 study design [clinicaltrials_resource:5302b24cf8198d0b0fbe56f960e9da13]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00149240

verification date [clinicaltrials_vocabulary:verification-date]

2007-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00149240

http://www.w3.org/2001/XMLSchema#string

title

Botulinum Toxin Type A (Dyspor ...... imary Myofascial Pain Syndrome

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Botulinum Toxin Type A (Dyspor ...... e [clinicaltrials:NCT00149240]

@en